HEALTHMEDPAGE TODAY
Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year
A year-long extension of the PURPOSE 1 and PURPOSE 2 trials found that twice-yearly injectable lenacapavir (Yeztugo) for HIV PrEP resulted in only one new HIV infection. The drug demonstrated high effectiveness in preventing HIV over the study period.
Mentioned
Related Signal
Adjacent reporting
- Lenacapavir will slow HIV infections if there's enough of it and it reaches at-risk groups
- Africa: Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results
- Africa: 'One Injection Protects Up to Six Months' - What Is New HIV Drug Lenacapavir?
- Mass rollout planned across Southern Africa for new HIV drug